The Motley Fool
31 Oct 2026, 12:30 UTC · 1h ago
Pfizer Just Hit a 52-Week High. Is the Turnaround Finally Real?
Impact · against what's priced in
Pfizer's recent 52-week high reflects a recovery based on cost-cutting and raised revenue guidance, but the core challenge remains the impending patent cliff. While short-term operational improvements are positive, they largely align with the market's current trajectory toward a stabilized EPS.
- PFE+0.20
No priced-in read yet
- In context
The company raised its full-year revenue guidance floor to $60.5 billion and is pursuing cost savings of up to $6.7 billion by 2029 to mitigate a projected 2027 EPS dip to $2.88.
Read from the article alone
